https://www.selleckchem.com/
Three patients (15%) experienced drug-related Grade ≥3 adverse events, while three patients (15%) had Grade ≥2 pneumonitis/RP within 3 months after durvalumab initiation. Three months after durvalumab initiation, all the patients were alive and four patients (20%) experienced disease progression. Conclusion Durvalumab can be a feasible treatment option for patients with stage III NSCLC with baseline Grade 1 RP following CCRT.(Trial registration number UMIN000036061. The registration period was between March 2019 and December 2019.).DNA hydroxymethylation pl
Beğen
Yorum Yap
Paylaş
